Long-Acting Injectable PrEP
Long-acting injectable PrEP is a prevention strategy under investigation that involves receiving a injection every two months of the antiretroviral cabotegravir. Results of HPTN 083, released in 2020, showed that this method is safe and effective at reducing HIV risk among gay men and other men who have sex with men and transgender women. A sister study, HPTN 084 also released early results in 2020 showing efficacy among cisgender women. Both HPTN 084 and 083 are continuing as open label studies while the product undergoes regulatory review.
Find more information on cabotegravir as a long-acting injectable PrEP at avac.org/long-acting-injectable-cabotegravir.